To REMS Or Not To REMS? Erivedge Shows Division At FDA Over Oncology Risk Management
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The review division and CDER senior staff supported approval of Genentech’s highly teratogenic, basal cell carcinoma treatment vismodegib without a Risk Evaluation and Mitigation Strategy, but the Division of Risk Management believed a communications plan should be carried out under a REMS for the first-in-class Hedgehog pathway inhibitor.
You may also be interested in...
Regulatory Round-Up: Drug Review Profiles From 2012
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile. If you do not have access, contact customer care at 1-800-332-2181 for a free copy of any of these articles.
Regulatory Round-Up: Drug Review Profiles From 2012
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.
Teratogenic Drugs Pose Little Risk To Partners Of Male Patients, FDA Panel Says
There is little to no evidence that a teratogenic drug would pass from a man to his female partner at a high enough level to endanger a fetus, the Drug Safety and Risk Management Advisory Committee tells FDA.